This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB08847/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08847/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n12http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB08847/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB08847/identifier/chebi/

Statements

Subject Item
n2:DB08847
rdf:type
n3:Drug
n3:description
Hydroxyproline is a neutral heterocyclic protein amino acid. It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis. Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds.
n3:group
experimental approved
n3:indication
Used in France as a combination product for the treatment of small, superficial wounds.
owl:sameAs
n12:DB08847
dcterms:title
Hydroxyproline
adms:identifier
n7:DB08847 n8:C01157 n9:18095 n10:Hydroxyproline
n3:synonym
trans-4-Hydroxy-L-proline L-Hydroxyproline
n3:mixture
n13:271B58C6-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Adams, Elijah; Goldstone, Alfred. Hydroxyproline metabolism. II. Enzymic preparation and properties of D1-pyrroline-3-hydroxy-5-carboxylic acid. Journal of Biological Chemistry (1960), 235 3492-8.
n3:IUPAC-Name
n4:271B58CB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B58D1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B58D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B58CD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B58CE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B58CF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B58C9-363D-11E5-9242-09173F13E4C5 n4:271B58E1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B58C7-363D-11E5-9242-09173F13E4C5 n4:271B58CA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B58C8-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B58E4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B58D7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B58D8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B58D2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B58D3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B58D5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B58D4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B58D6-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-35-4
n3:Bioavailability
n4:271B58DD-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B58E3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B58DF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B58E0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B58E2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B58DC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B58DB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B58DE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B58CC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B58D9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B58DA-363D-11E5-9242-09173F13E4C5